SURFACE MARKER ANALYSIS IN CHILDHOOD ACUTE MYELOGENOUS LEUKEMIA (AML) - DIAGNOSTIC-VALUE AND PROGNOSTIC IMPACT ON THERAPY

被引：0
|
作者：
LUDWIG, WD [1 ]
CREUTZIG, U [1 ]
RITTER, J [1 ]
GATZKE, A [1 ]
SCHELLONG, G [1 ]
机构：
[1] KLINIKUM STEGLITZ,HAMATOL ONKOL ABT,D-1000 BERLIN 45,FED REP GER
来源：
BLUT | 1987年 / 55卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：290 / 290
页数：1
相关论文
共 50 条
  • [21] BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia (AML).
    Kornblau, SM
    Vu, H
    Ruvolo, P
    Cortes, J
    O'Brien, S
    Kantarjian, H
    Estrov, Z
    Andreeff, M
    May, WS
    BLOOD, 1998, 92 (10) : 678A - 678A
  • [22] SURFACE MARKER COEXPRESSION IN ADULT ACUTE NONLYMPHOBLASTIC LEUKEMIA - ANY PROGNOSTIC VALUE
    PLATA, E
    CHOREMIPAPADOPOULOU, H
    VIGLIS, V
    VINIOU, N
    ROMBOS, J
    MELETIS, J
    LOUKOPOULOS, D
    YATAGANAS, X
    BLOOD, 1994, 84 (10) : A623 - A623
  • [23] PROGNOSTIC VALUE OF SERUM LYSOZYME ACTIVITY IN ACUTE MYELOGENOUS LEUKEMIA
    ALSABTI, E
    MEDICAL AND PEDIATRIC ONCOLOGY, 1979, 6 (03): : 189 - 193
  • [24] Exercise and sports team participation in survivors of childhood acute myelogenous leukemia (AML)
    Schultz, Kris Ann P.
    Zhou, Tianni
    Chen, Zhengjia
    Zeltzer, Lonnie K.
    Nicholson, H. Stacy
    Neglia, Joseph P.
    PEDIATRIC BLOOD & CANCER, 2007, 48 (06) : 641 - 641
  • [25] The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML)
    Elliot, Kathleen
    Tooze, Janet A.
    Geller, Rachel
    Powell, Bayard L.
    Pardee, Timothy S.
    Ritchie, Ellen
    Kennedy, LeAnne
    Callahan, Kathryn E.
    Klepin, Heidi D.
    LEUKEMIA RESEARCH, 2014, 38 (10) : 1184 - 1190
  • [26] SHORT-TERM THERAPY (STT) FOR ACUTE MYELOGENOUS LEUKEMIA (AML)
    ROHATINER, AZS
    BATTISTA, R
    BASSAN, R
    LOVE, S
    OZA, AM
    WHELAN, JS
    LIM, J
    BUELLI, M
    VIERO, P
    DEMILLIO, A
    DAVIS, CL
    AMESS, J
    DINI, E
    BARBUI, T
    LISTER, TA
    LEUKEMIA, 1992, 6 : 85 - 88
  • [27] Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?
    Rowe, JM
    LEUKEMIA, 2005, 19 (08) : 1324 - 1327
  • [28] Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?
    J M Rowe
    Leukemia, 2005, 19 : 1324 - 1327
  • [29] Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia
    Kondo, M
    Horibe, K
    Takahashi, Y
    Matsumoto, K
    Fukuda, M
    Inaba, J
    Kato, K
    Kojima, S
    Matsuyama, T
    MEDICAL AND PEDIATRIC ONCOLOGY, 1999, 33 (06): : 525 - 529
  • [30] AF1q is a novel poor prognostic marker for adult acute myelogenous leukemia (AML) patients with normal cytogenetics
    Strunk, CJ
    Platzbecker, U
    Thiede, C
    Schaich, MA
    Illmer, T
    Kang, ZZ
    Leahy, P
    Li, CB
    Reiner, S
    Laughlin, MJ
    Lazarus, HM
    Bunting, KD
    Gerson, SL
    Ehninger, G
    Tse, WW
    BLOOD, 2005, 106 (11) : 921A - 921A
12345